# Correction: Arce-Huamani et al. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Medicina 2023, 59, 1867

**Authors:** Miguel A. Arce-Huamani, Joshuan J. Barboza, José Fabián Martínez-Herrera, J. Smith Torres-Roman, Jorge L. Maguiña

PMC · DOI: 10.3390/medicina60010134 · Medicina · 2024-01-11

## Full-text entities

- **Diseases:** VTE (MESH:D054556), Cancer (MESH:D009369), injury to people or property (MESH:C000719191), bleeding (MESH:D006470)
- **Chemicals:** DOACs (-), Dalteparin (MESH:D017985), LMWHs (MESH:D006495), Apixaban (MESH:C522181)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10821357/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC10821357/full.md

---
Source: https://tomesphere.com/paper/PMC10821357